Mazdutide
IBI362 · LY3305677
A dual GLP-1 and glucagon receptor agonist based on oxyntomodulin, studied in registered trials for weight management and glycemic control. Adding glucagon activity is intended to raise energy expenditure alongside the GLP-1 effect.
Tracking and educational reference only, on values you enter yourself. Not medical advice or a dosing recommendation.
Half-life
Weekly administration in registered trials; no human PK in a public label. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Investigational; handling follows the study protocol rather than a public label.
References
- PubChem compound record
- Registered clinical trial programme
Read the source
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.